Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Spero Therapeutics stock | $16.42

Learn how to easily invest in Spero Therapeutics stock.

Spero Therapeutics Inc is a biotechnology business based in the US. Spero Therapeutics shares (SPRO) are listed on the NASDAQ and all prices are listed in US Dollars. Spero Therapeutics employs 89 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Spero Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SPRO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Spero Therapeutics stock price (NASDAQ: SPRO)

Use our graph to track the performance of SPRO stocks over time.

Spero Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$16.42
52-week range$11.75 - $23.64
50-day moving average $18.09
200-day moving average $15.31
Wall St. target price$41.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.79

Buy Spero Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Spero Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Spero Therapeutics price performance over time

Historical closes compared with the close of $16.42 from 2021-10-25

1 week (2021-10-19) -4.20%
1 month (2021-09-24) -12.33%
3 months (2021-07-26) 16.62%
6 months (2021-04-26) 16.95%
1 year (2020-10-26) 23.83%
2 years (2019-10-25) 52.18%
3 years (2018-10-26) 98.79%
5 years (2016-10-22) N/A

Spero Therapeutics financials

Revenue TTM $18.4 million
Gross profit TTM $-57,673,000
Return on assets TTM -43.61%
Return on equity TTM -92.11%
Profit margin 0%
Book value $3.04
Market capitalisation $542 million

TTM: trailing 12 months

Shorting Spero Therapeutics shares

There are currently 2.5 million Spero Therapeutics shares held short by investors – that's known as Spero Therapeutics's "short interest". This figure is 1.8% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting Spero Therapeutics shares can be evaluated.

Spero Therapeutics's "short interest ratio" (SIR)

Spero Therapeutics's "short interest ratio" (SIR) is the quantity of Spero Therapeutics shares currently shorted divided by the average quantity of Spero Therapeutics shares traded daily (recently around 135175.773746). Spero Therapeutics's SIR currently stands at 18.74. In other words for every 100,000 Spero Therapeutics shares traded daily on the market, roughly 18740 shares are currently held short.

However Spero Therapeutics's short interest can also be evaluated against the total number of Spero Therapeutics shares, or, against the total number of tradable Spero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spero Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Spero Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0989% of the tradable shares (for every 100,000 tradable Spero Therapeutics shares, roughly 99 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Spero Therapeutics.

Find out more about how you can short Spero Therapeutics stock.

Spero Therapeutics share dividends

We're not expecting Spero Therapeutics to pay a dividend over the next 12 months.

Spero Therapeutics share price volatility

Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $11.75 up to $23.639. A popular way to gauge a stock's volatility is its "beta".

SPRO.US volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 1.5639. This would suggest that Spero Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Spero Therapeutics overview

Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co. , Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.

Frequently asked questions

What percentage of Spero Therapeutics is owned by insiders or institutions?
Currently 16.418% of Spero Therapeutics shares are held by insiders and 55.784% by institutions.
How many people work for Spero Therapeutics?
Latest data suggests 89 work at Spero Therapeutics.
When does the fiscal year end for Spero Therapeutics?
Spero Therapeutics's fiscal year ends in December.
Where is Spero Therapeutics based?
Spero Therapeutics's address is: 675 Massachusetts Avenue, Cambridge, MA, United States, 02139
What is Spero Therapeutics's ISIN number?
Spero Therapeutics's international securities identification number is: US84833T1034
What is Spero Therapeutics's CUSIP number?
Spero Therapeutics's Committee on Uniform Securities Identification Procedures number is: 84833T103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site